The chronic autoimmune inflammatory diseases, systemic lupus erythematosus and Sjogren's syndrome, develop when tolerance to apoptotic cells (ACs) lo ) constitute 80% of splenic and 96% of peritoneal B cells that respond to ACs by secreting IL-10. AC responsive B1a cells secrete self-reactive natural antibodies (NAbs) and IL-10, which is augmented by toll-like receptor (TLR) 7 or TLR9 stimulation. In so doing, they both accelerate the clearance of dying cells by macrophages and inhibit their potential to mount proinflammatory immune responses. While B1a cells make prolonged contact with ACs, they do not require TIM1 or complement to mediate their regulatory function. In an animal model of neural inflammation (experimental autoimmune encephalomyelitis), just 10 5 activated B1a B cells was sufficient to restrain inflammation. Activated B1a B cells also induced antigen-specific T cells to secrete IL-10. Hence, regulatory B1a cells specifically recognize and augment tolerance to apoptotic self via IL-10 and NAbs; but once activated, can also prevent autoimmune mediated inflammation.
The chronic autoimmune inflammatory diseases, systemic lupus erythematosus and Sjogren's syndrome, develop when tolerance to apoptotic cells (ACs) is lost. We have previously reported that this tolerance is maintained by innate-like, IL-10 secreting regulatory B cells. Two questions remained. lo ) constitute 80% of splenic and 96% of peritoneal B cells that respond to ACs by secreting IL-10. AC responsive B1a cells secrete self-reactive natural antibodies (NAbs) and IL-10, which is augmented by toll-like receptor (TLR) 7 or TLR9 stimulation. In so doing, they both accelerate the clearance of dying cells by macrophages and inhibit their potential to mount proinflammatory immune responses. While B1a cells make prolonged contact with ACs, they do not require TIM1 or complement to mediate their regulatory function. In an animal model of neural inflammation (experimental autoimmune encephalomyelitis), just 10 5 activated B1a B cells was sufficient to restrain inflammation. Activated B1a B cells also induced antigen-specific T cells to secrete IL-10. Hence, regulatory B1a cells specifically recognize and augment tolerance to apoptotic self via IL-10 and NAbs; but once activated, can also prevent autoimmune mediated inflammation.
Keywords: regulatory, B cell, B1a, apoptotic cell, immune tolerance inTrODUcTiOn Some years ago, Wolf et al. noted that B cell-deficient mice develop a chronic form of neural inflammation called experimental autoimmune encephalomyelitis (EAE) (1) , which was later attributed to the loss of B cell IL-10 production (2). IL-10 is a broad spectrum anti-inflammatory cytokine that potently suppresses the activation of macrophages and dendritic cells (3, 4) . Further studies have failed to identify a specific subset of IL-10 secreting regulatory B cells that express a particular transcription factor, akin to Foxp3 regulatory T cells (5) (6) (7) . Instead, B cells with a capacity to regulate immune responses via IL-10 secretion have been described among activated B cells that express the surface markers CD5 and CD1d (8, 9) , T2-marginal zone precursor B cells (10, 11) , and plasma cells (12, 13) . Our own focus has been to understand whether regulatory B cells play a role in preventing a breakdown in tolerance to apoptotic cells (ACs) (7, 14, 15) , the loss of which leads to autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome, and systemic sclerosis (16) . Following programmed cell death, ACs express immunogenic intracellular (IC) self-antigens on their cell surface (17) (18) (19) . The mechanism for maintaining tolerance to apoptotic self is believed to rely almost exclusively on their rapid clearance by phagocytes (20, 21) , which is accelerated by polyreactive natural antibodies (NAbs) that bind to AC expressed neoantigens (22) . While central and peripheral tolerance mechanisms also purge many self-reactive B and T cells; a population of innate-like B cells, within the marginal zone (MZB) and B1a subsets, are selected on their ability to respond to self, developing normally even in the absence of foreign antigenic stimulation (23, 24) . B1a cells are a major source of , inhibiting the progression of both innate and adaptive immune responses, preventing tissue damage, but at the cost of impeding pathogen clearance (26) . The presence of self-reactive innate-like B cells is not normally associated with autoimmunity, in spite of their frequent exposure to ACs in secondary lymphoid organs and sites of inflammation. Conversely, B1a B cells are also known as essential first responders to pathogens in the lung and gut, secreting proinflammatory GM-CSF (24, (27) (28) (29) . Thus, a mechanism to ensure that ACs are sensed as tolerogenic by innate-like B cells is likely to be important.
We have previously reported, that splenic CD21 hi CD23 low B cells and CD5 +ve peritoneal B cells can be activated by antigenspecific T cells (via CD40) or directly via toll-like receptor (TLR) ligands to secrete IL-10 in response to ACs. In vivo, mice given ACs at the time of inducing collagen-induced arthritis or EAE are protected from inflammation, generating lower titers of auto-antibodies, along with an increase in antigen-specific IL-10 secreting T cells (14) . The B cells sense AC expressed DNase-sensitive determinants via their BCR and make IL-10 in a TLR9-dependent process (15) . However, we do not know which particular antigens self-reactive regulatory B cells recognize or whether immune regulatory function is mediated predominantly by a particular subset of B cells.
This study addressed those questions and identified that 80% of splenic and 96% of peritoneal, AC responsive, innate-like regulatory B cells were B1a B cells. AC responsive regulatory B cells (ACBregs) make prolonged contact with ACs and secrete both IL-10 and self-reactive NAbs. This both enhances AC clearance and likely prevents a breach in self-tolerance. Additionally, they induce naive T cells to secrete IL-10, but they do not require the expression of Tim1 or C1q to exert their regulatory function.
MaTerials anD MeThODs

Mice
IL-10-GFP, TIM1
−/− C57BL/6 (see Figure S2Cii in Supplementary Material for assessment of genotype), TIM1
−/− BALB/c (see Figure  S2Ci in Supplementary Material for assessment of genotype), C1q
) (see Figure S2J in Supplementary Material for confirmation of phenotype), DO11.10 TcR Tg mice, and OTII-Ly5. 
Flow cytometry and Facs sorting
For all staining, cells were stained in PBS with 2% FCS for 20 min at 4°C. BD Aria II was used for flow sorting and BD LSRII was used to collect data. For sorted cells, debris and dead cells were excluded using FSC-SSC. Doublets were excluded using both FSC and SSC singlet gating, then CD19
+ve B cells isolated. For Figures 1C and 2A, CD4 and CD3 stains were also included to exclude contaminating T cells. Antibodies used were specific for and labeled with CD21-FITC, CD3-PE TxR, CD4-PE, IgM-APC, GM-CSF-PE, IL-10-PE, IL-17-alexa fluor647, IFN-γ-FITC (BD Biosciences); CD11b-BV570, CD11b-PE Cy5, CD19-PE, CD19-BV605, CD1d-PerCP Cy5.5, CD21/35-APC, CD23-PE, CD23-alexa fluor 647, CD23-PE Cy7, CD3-FITC, CD3 PE/ Dazzle 594, CD38-PE, CD4-PE, CD4-BV605, CD40-PE Cy7, CD43-FITC, CD43-APC, CD5-PE Cy5, CD80-PerCP Cy5.5, CD86-BV421, TIM1-PE, TNFα-BV605 (Biolegend); CD21/35-APC efluor780, CD24-APC efluor780, CD25-efluor450, CD9-APC, DO11.10 TCR-Biotin, IgD-efluor450, MHCII-PE Cy5, CD19-eFluor450, F4/80-APC, IFN-γ-PE Cy7, streptavidin-PE (eBioscience); IgM-TxR, IgM-alexa fluor647 (Southern Biotech); IgM-alexa488, cell tracker green (Molecular Probes), and CFSE (fluka). All analysis was performed using FlowJo Software.
ic staining
Cells were stimulated for 4.5 h total with PMA [Sigma (20 ng/ml)] and Ionomycin [Sigma (1 μg/ml)]. After 1 h stimulation, Brefeldin A [Sigma (1 μg/ml)] was added for the remaining 3.5 h. Surface staining was performed before resuspending in fixation and permeabilization solution for 20 min (Cytofix/Cytoperm kit, BD Biosciences) followed by IC staining. All IC antibodies were used at 1:100 for 30 min in 1× Perm/Wash buffer (Cytofix/Cytoperm kit, BD Biosciences).
Thymus ac generation
Thymi were removed from 4-to 6-week-old syngeneic mice, teased into single cell suspensions and cultured for 18 h in IMDM (supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 20 mM 2-mercaptoethanol, and 10% heat inactivated FCS). Cells prepared in this way give an average of 43% Annexin-V (AnV) +ve /propidium iodide (PI) −ve ACs and <5% AnV +ve /PI +ve secondary necrotic cells (14) . Where ACs are needed for experiments involving C1q −/− ACs were generated following culture in X-Vivo 15 media without serum. 
Jurkat ac generation
Treatment with anti-CD95 (1 μg/ml) induced Jurkat cells to become apoptotic after 18 h in culture with serum free RPMI (supplemented with 2 mM l-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin). At this point 80% were AnV +ve . Cells used in phagocytosis or interaction assays were labeled with cell tracker green (Molecular Probes) prior to induction of apoptosis.
B cell isolation
Mouse splenocytes were "teased apart" to obtain single cell suspensions and depleted of red cells with red cell lysis buffer (Sigma-Aldrich, St. Louis, MO, USA). B cells were isolated from spleen single cell suspensions or peritoneal lavages using positive selection with CD19 + microbeads as per manufacturer's instructions (Miltenyi Biotech). Cells were then further sorted by FACS as per figure legends.
In Vitro Tlr stimulation assays immunofluorescence Apoptotic Jurkats were incubated with 20 μg/ml of IgM derived from the hybridoma supernatant followed by anti mouse IgMalexa fluor 488 (1:400 dilution. Molecular probes). The plasma membrane was stained with Cell Mask Deep Red plasma membrane stain (1:1,000 in PBS) for 10 min at 37°C and following fixation with 3.7% formaldehyde the nucleus stained with DAPI. Cells, mounted in ProLong ® Gold Antifade Mountant were visualized on a Leica SP5 confocal microscope.
antigen elisa EIA/RIA (costar) 96-well plates were coated with 2 μg/ml (in 50 μl PBS) antigen overnight then blocked (PBS + 1% BSA) for 1.5 h. Antigens used were malondialdehyde-modified low-density lipoprotein (MDA-LDL), oxidized-LDL (Ox-LDL), citrullinated fibrinogen (Cambridge Biosciences); DNA, ssDNA, thyroglobulin, yeast RNA, alpha Actinin (Sigma); La, Ro, Smith, histone (Arotec Diagnostics); rheumatoid factor (Thermofisher Scientific), CWPS (Oxford Biosystems), ApoH (R&D Systems), PC-BSA (2B Scientific), and AnV (eBiosciences). Serum samples were initially diluted at 1:250. For in vitro-generated antibodies, supernatants were initially diluted 1:2. For hybridoma-generated antibodies, IgM was determined and supernatants were diluted to 0.5 μg/ml prior to serial dilutions. Secondary antibody (1:1,000 dilution) were either anti mouse IgM-HRP (Southern Biotech) or anti mouse IgG-HRP (Zymed). MRL/lpr mouse serum (diluted 1:250) was used as a positive control while IgM derived from IL-10 -ve clones that did not bind to ACs were used as negative controls. −/− shown with filled bars. Data representative of n = 3. Statistical differences were determine by unpaired Student's t-test *P < 0.05, **P < 0.01, and ***P < 0.001. 
In Vivo antigen challenge experiments
(IV). For experiments with C1q
−/− mice, C1q −/− thymocytes were cultured in serum free X-Vivo 15 media. Mice were immunised with 50 μl OVA323-339 peptide (1 mg/ml) emulsified in an equal volume of complete Freund's adjuvant (CFA) sc into each hind leg. On D7 splenic single cell suspensions were generated prior to restimulation using 1 × 10 6 splenic cells along with OVA323-339 peptide at 4, 2, 1, 0.5, and 0 μg/ml. After 72 h, cytokines were measured (R&D duoset ELISA).
T cell Proliferation
Splenic cells were labeled with 1 μM CFSE before setting up in culture with 2 μg/ml OVA323-339. Cells were harvested every 24 h and further stained with CD3 and Ly5.1 (for OTII). The mean florescence intensity (MFI) of CFSE for CD3 +ve Ly5.1 +ve cells was measured using flow cytometry.
B cell interaction assays
Purified B cells were incubated with cell tracker green labeled AC-Jurkats in a ratio of 1:5. After 4 or 24 h, cells were stained for CD19 and CD43. Interaction was measured using flow cytometry by determining the percentage of B cells which were also positive for cell tracker green, indicating interaction between the B cell and AC.
Preparation of Primary Bone MarrowDerived Macrophages (BMDMs)
Bone marrow-derived macrophages were isolated from the hind leg bones of C57BL/6 mice and cells cultured in compete IMDM + 10% L929-conditioned media (containing M-CSF) for 7 days in flat bottom plates.
Phagocytosis assay
1 × 10 6 cell tracker green labeled AC-Jurkats were incubated with 20 μg/ml of hybridoma derived IgM and cocultured with BMDM for 30 m.
Macrophage-B cell cocultures
Peritoneal CD43
+ve B1a or splenic follicular B (FOB) cells were activated with R848 (0.1 μg/ml) for 24 h and then cocultured with R848 (0.5 μg/ml) activated BMDM for 18 h. 20 μg/ml anti-IL-10 or isotype control antibody (Biolegend) was added for length of culture. Supernatants were assessed for released cytokines by ELISA (R&D duoset) and cells were stained for IC cytokines.
induction and assessment of eae
Experimental autoimmune encephalomyelitis was induced as described previously (15) . On D3/4 mice were either given 1 × 10 5 CD43 +ve B1 cells or splenic FOB, that had been previously activated with R848 (0.1 μg/ml) for 48 h. Following sacrifice, harvested organs were weighed and single cell suspensions from the spleen and LN generated. Spinal cords were collagenase/ DNase digested before running over 70/30% Percoll gradient to obtain leukocytes. Re-stimulation assays were set up using 1 × 10 6 splenic or LN cells or 1 × 10 5 spinal cord cells along with MOG35-55 peptide at 20, 10, 5, 2.5, and 0 μg/ml. After 72 h, cytokines were measured (R&D duoset ELISA) and IC staining performed.
Bhlhe41 mrna Determination
RNA was extracted from 10 5 purified cells [TRI ® Reagent (Ambion)] followed by reverse transcription [High Capacity cDNA reverse transcription kit (Applied Biosystems)]. Bhlhe41 cDNA levels were quantitated by Taqman ® Gene Expression Assay predesigned primers (Mm00470512_m1) with intra-sample expression normalized to Eukaryotic 18S rRNA Endogenous control (FAM™/MGB probe) and run on an Applied Biosystems 7900HT Fast-Real Time System using SDS software (v2.4). Data were analyzed using the comparative CT method (Δ/ΔCT), where fold differences in gene expression between FOB and other B cell populations (ΔCT) were normalized to CT values of the 18S rRNA reference gene.
statistical analysis
Experimental repeats are given under each experiment and ranged from 3 to 12. Data are expressed as mean and SEM. Statistical significance between the groups was assessed by GraphPad Prism Version 7.0 using the appropriate analysis as stated in the figure legends. P-values: *0.01-0.05, **0.001-0.01, and ***<0.001. Figure 1C, iii) .
To assess the differential responses of activated splenic B cells to ACs, highly purified splenic MZB (CD19 
B1a B cells augment T cell il-10 Production
We +ve splenic B1a cells ( Figure S2B in Supplementary Material). These B cell subsets were used as antigen-presenting cells (APCs) to stimulate naive OVA323-339-specific T cells and IL-10 production was assessed after 72 h (Figures 2A,B, i,iii) . IC staining confirmed that the highest percentage of IL-10 producing cells was still seen among the splenic and PerC CD43
+ve B1a B cells. These same B1a B cells also induced a significantly higher percentage of CD4 +ve T cells to produce IL-10 (Figures 2A,B , ii). Mammalian DNA has been shown to bind to CR2/CD21, which is most highly expressed by MZB and PerC B1 B cells (34, 35) . ACs express DNA containing chromatin complexes on their cell surface and altered expression of CR2 is associated with SLE in mice (36) . In addition, complement proteins, including C1q, bind to late ACs and increase their uptake by phagocytes (21, 37, 38) ; the loss of which is believed to contribute to the increased risk of SLE (20) . Hence complement may also play an essential role in regulatory B cell function. To test this, we assessed the cytokine responses of WT or CR2 −/− splenic B cells, activated with TLR7/8 or TLR9 and cocultured with ACs. To avoid bias that may occur with B cell surface markers from these knockout mice, we assessed CD19 (40), which we and others have previously reported to be required for regulatory B cell function (14, 41, 42) .
Apoptotic cells express a range of self-antigens on their cell surface, including DNA, the proteins Ro and La, and the phospholipid phosphatidylserine, all of which are potent autoantigens in SLE and Sjogren's syndrome (17, 19) . Following PCD membrane LDLs also undergo peroxidation, resulting in the formation of neoepitopes including MDA-LDL, Ox-LDL, and phosphorylcholine (PC) (22) . In contrast to the PerC, the spleen is a major site of antibody production by B1a B cells (28) and following an infusion of ACs, a rise in the titer of IgM (but not IgG) with specificities typical of NAbs was observed in the serum ( Figure 3B ) (22) . To ask whether IL-10 +ve splenic B cells were the source of these antibodies, IL-10 +ve and IL-10 −ve splenic B cells were sorted seven days after the administration of ACs (as shown in Figure S1Ci -ii in Supplementary Material). These cells were cultured in vitro with a proliferation inducing ligand (APRIL), IL-4, and CpGB to stimulate antibody secretion. After 10 days, supernatants were harvested and tested for the specificity of secreted immunoglobulin. Only IL-10 +ve splenic B cells secreted significant quantities of IgM (Figure 3C, i) but not IgG (data not shown). The antibodies secreted into the supernatants were of similar specificities to those antibodies seen in the serum of mice injected with ACs ( Figure 3C, ii) ; confirming that IL-10 +ve regulatory B cells respond to AC expressed neoantigens by secreting NAbs. To further assess the specificity of these regulatory cells, IL-10 +ve and IL-10 −ve splenic B cells were sorted from mice that had been given an infusion of ACs 7 days earlier. As noted before, IL-10 +ve B cells had the markers of B1a B cells ( Figure S3B in Supplementary Material). B cells were then fused with the SP2/0 cell line to form hybridomas (as illustrated in Figures S3C,D in Supplementary Material). Individual clones were tested for reactivity to a variety of epitopes found on ACs and within the NAb repertoire. Again, only IgM secreted by the hybridomas originating from the IL-10 +ve (but not IL-10 −ve ) splenic B1a cells, showed cross-reactivity with a range of epitopes expressed on ACs, particularly MDA-LDL, Ox-LDL, and the autoantigens Ro, La, histones, and Smith (Sm) protein ( Figure 3D) . Hence, ACBregs that respond to ACs are B1a cells that secrete both IL-10 and IgM with specificities that resemble NAbs.
acBregs inhibit Macrophage Proinflammatory Function
Natural antibodies augment the clearance of ACs (43) and IgM secreted by ACBregs preferentially bound to ACs, while the antibodies derived from IL-10 −ve splenic B cells did not ( Figure 4A, i-ii; Figures S4A,B in Supplementary Material). The phagocytosis of ACs by BMDM, that had bound ACBreg derived IgM, was also significantly increased ( Figure 4A, iii) , as expected (44) . BMDMs are particularly sensitive to the effects of IL-10, which is largely responsible for the anti-inflammatory response, acting via the IL-10 receptor and increasing signaling through the JAK1/STAT3 cascade (45) . In contrast, TLR7/8 stimulation with R848 induces BMDMs to secrete TNFα. We noted that, in distinction to FOB cells, the coculture of B1a B cells with BMDMs, where both cell types had been activated with R848, resulted in a significant decrease in the amount of TNFα secreted into the culture medium (Figure 4B, i) , as well as the percentage of macrophages (F4/80 + CD19 − ) positive for IC TNFα (Figure 4B , ii-iii). Supernatants transferred from R848 activated B1a B cells to similarly activated macrophages also diminished TNFα production ( Figure 4B, i-iii) , as well as the activation marker CD86 (Figure 4C) . IL-10 secreted by activated B1a cells ( Figure 4D ) was required to prevent TNFα secretion, as evidenced by the loss of macrophage TNFα suppression in the presence of anti-IL-10 antibodies (Figure 4E, i-ii) .
activated B1a B cells suppress autoimmunity
The neuroinflammatory disease model EAE is driven by both activated, antigen-specific T cells and macrophages. We next asked if activated B1a could limit auto-immune mediated inflammation. Mice were immunized with MOG peptide emulsified in CFA (MOG/CFA) to induce EAE. PerC B1a cells and splenic FOB cells were stimulated with the TLR7/8 ligand R848 for 48 h in vitro and either 10 5 B1a cells or 10 5 FOB cells were injected intravenously 3-4 days following immunization with MOG/CFA. Despite activating the B1a cells with a proinflammatory stimulus (via TLR7/8 with R848), clinical disease severity was significantly reduced (Figure 5A ). On day 20 the spinal cords of control FOB cell-treated mice (FOB) also contained a greater number of total cells compared to those given B1a cells (Figure 5B) , though cell numbers in the spleen and draining lymph nodes were unchanged (data not shown). The spinal cords were further analyzed for CD4 +ve and CD19 +ve cells. Compared to B1a-treated mice, the percentage of CD4 +ve T cells in the spinal cords of mice given control FOB cells was more than six times higher, while CD19 +ve B cell infiltration was approximately halved in B1a-treated mice ( Figure 5C , i-ii). Lymphocytes from the spleen, draining lymph nodes and spinal cord were re-stimulated with MOG peptide for 72 h and the cytokines IL-17, IFN-γ, and GM-CSF quantified by ELISA. In keeping with the reduced inflammation seen clinically, B1a-treated mice generated significantly less proinflammatory cytokines than control FOB cell-treated mice in all organs tested, but particularly the spinal cords ( Figure 5D, i-iii) . IC cytokine staining confirmed that a source of these cytokines was the CD4 +ve T cell, which again showed a significantly lower production of IL-17, IFN-γ, and GM-CSF in B1a-treated mice ( Figure 5D , iv-vii). This confirms that activated B1a B cells are able to suppress autoimmune mediated inflammation when administered after the initiation of EAE.
DiscUssiOn
This report pinpoints self-reactive, CD43
+ve B1a cells, which express the transcription factor Bhlhe41, found in the spleen and PerC, as a major responder to ACs. Of the remaining 20% of splenic CD43
−ve B cells, that similarly responded to ACs, it is likely that many of these reside within the MZB cell population. Dying cells are a potent source of expressed neoantigens (17, 46) , which are recognized by ACBregs via their BCR and TLR receptors, leading to the secretion of both IL-10 and NAbs (14, 15) . We show that this both accelerates the clearance of ACs by macrophages and simultaneously reduces macrophage proinflammatory responses. Furthermore, ACBregs induce antigenspecific T cells to secrete IL-10 and suppress the induction of autoimmune CNS inflammation. Hence AC-specific B1a B cells fulfill two important homeostatic functions; they ensure, via Nab secretion, the rapid disposal of apoptotic corpses and, via IL-10 secretion, they prevent inflammatory autoimmune responses. Activated macrophages orchestrate much of the tissue injury seen in autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriatic arthritis and inflammatory bowel disease (47) . IL-10 is a key regulator of activated macrophages (48) and as such, activated IL-10 secreting ACBregs are likely to play a physiologically relevant role, both in preventing a break in self-tolerance and containing ongoing autoimmune responses.
In contrast, we found that T2 marginal zone precursor B cells (T2-MZB) secreted much less IL-10 in response to activation by TLR ligands and coculture with ACs. This confirms that while T2-MZB precursor B cells regulate particular immune responses, they do not play a clear role in mediating tolerogenic responses to apoptotic self (11, 49) . Tedder et al. have previously described a population of IL-10 secreting "B10" cells, which are enriched in the expression of CD1d and CD5 (8, 9) . They are functionally defined in mice and humans by their ability to secrete IL-10 following 5 h of ex vivo stimulation with lipopolysaccharide (LPS), phorbol ester, and ionomycin (PMA/Iono). The term B10 usefully includes all B cells that have the capacity to secrete IL-10 following this stimulus. However, it necessarily encompasses B cell subtypes with differing origins and functional attributes and does not enable one to determine the particular characteristics of regulatory B cells that are concerned with self-tolerance. In addition, TLR activated B cells increase their expression of CD1d (see Figure S1Cvi in Supplementary Material), which further complicates drawing firm conclusions about subset origin.
Early studies confirmed that B1a B cells were self-reactive as well as being a major source of IL-10 (3, 24, 25, 28). They constitutively express STAT3 which binds to the IL-10 promoter, further enhancing the generation of IL-10 (26, 50). Once activated, they migrate away from the coelomic cavities into the spleen, bone marrow, and other lymphoid organs, where they secrete immune modulatory IL-10 and NAbs (51, 52) ; so maintaining a tolerogenic environment toward AC expressed neoantigens. B1a development and NAb secretion does not require foreign antigenic stimulation, which occurs under gnotobiotic conditions (53) . Indeed, it has long been suspected that ACs play an important role in their development and these data further support a central relationship between dying cells and B1a cell function.
Apoptotic cell responsive regulatory B cells generate polyclonal IgM that binds particularly well to AC expressed neoantigens including MDA-LDL, Ox-LDL, PC, Ro, La, histones, and Smith antigen; which accelerates their clearance. The prototypic NAb T15, identified over 40 years ago, arises within a week of birth in the absence of pathogens, and also binds to PC that is expressed on pneumococci (54, 55) . T15-NAbs similarly bind to oxidatively modified LDL, reducing the inflammation associated with atherosclerosis (56) and arthritis (57, 58 ) via a direct effect on dendritic cells and macrophage function.
Phosphatidylserine which is exposed on the surface of ACs, is recognized by members of the TIM domain family (that includes TIM1, TIM3, and TIM4) (59) . Considering previous reports of a requirement for TIM1 expression by regulatory B cells (32, 33, 60) , we were surprised to find that TIM1-deficient B cells on both the BALB/c and the C57BL/6 background responded normally to ACs, both in vitro and in vivo, by secreting IL-10. These differences could have arisen from alternative gene knockout strategies, because in TIM1-deficient mice where immune regulation is altered, only the mucin domain of TIM1 has been deleted. In contrast, we analyzed TIM-1-deficient mice that lacked the full-length molecule. Complement deficiency is also believed to influence the predisposition to autoimmunity because of an inability to coat ACs with C1q or the later complement components. Such opsonization is required for the efficient clearance of ACs by phagocytes (61) . Again, we were intrigued to find that, rather than a loss of regulatory B cell function, the absence of either C1q or CR1/CR2 led to enhanced IL-10 secretion. This was explained by the increased frequency of splenic and PerC B1a B cells in both knockout phenotypes and confirms that C1q or CR1/CR2 are not needed for B1a B cells to secrete IL-10 in response to ACs or TLR ligand stimulation. In relation to autoimmunity, B1a B cells in the NZB/W F1 lupus model class switch to IgG and accumulate in the spleen and target organs (62) . In addition, B1a B cells are crucial in the NOD mouse model of diabetes (63) . We would speculate that tissue-specific signals and/or unique pathogen derived signals combine to determine whether the response of B1a cells is predominantly regulatory (via IL-10/NAbs) or proinflammatory (via GM-CSF/NAbs) (27, 29, 64) .
In summary then, we have delineated that a major population of regulatory B cells that responds to ACs are B1a cells. This population of B1a cells functions to optimize the disposal of ACs (via Nabs), while inhibiting macrophage proinflammatory responses and promoting regulatory T cell responses to self-antigens (via IL-10). If an equivalent population of B cells could be harnessed in humans, it would provide a valuable means to regulate autoimmunity and transplant rejection. +ve (ii) or CD5 +ve (iii) PerC B cells in Naiïve or apoptotic cellAC -treated mice used in Figure 1e and (S1D). −/− with filled circles. N = 6 mice. Statistical differences were determine by unpaired Student's t-test *P < 0.05, **P < 0.01, and ***P < 0.001. 
